Children with Cancer Consortium in Europe. A close collaboration between pharma, regulators and academic groups is necessary to incorporate these therapies into clinical practice.
-New agents have been developed to target pathogenic molecular alterations at different cell levels: cell surface receptors, tyrosine-kinases, signaling pathways and the cell cycle. Immunotherapy in leukemia is key and new promising agents are being developed such as antibodies or CAR-T cells.
-The introduction of targeted agents in particular subsets of children with leukemia harboring individual molecular alterations has radically changed their outcome, such as BCR-ABL fusion gene in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. The identification of driving targetable molecular alterations in clonal leukemic cells will allow individualizing treatments while sparing patients of undesirable side effects.
Introduction
Leukemia is the most common type of cancer in children [1] . 90-95% of those are acute leukemias. Acute lymphoblastic leukemia (ALL) is the most frequent (75-80%), followed by acute myeloid leukemia (AML) (20%) [1] . Less frequent are chronic myeloid leukemia (CML) and juvenile myelomonocytic leukemia (JMML) [1] .
The optimization in the use of existing conventional chemotherapeutic anti-leukemic agents together with improvements in risk-group stratification and supportive care have led to a significant increase in cure rates. Five-year event free survival (EFS) in pediatric ALL has increased from less than 10% in earlier efforts to more than 80% with current front-line regimens [2] . With very few exceptions, the drugs used today were available by the late 1960s. This improvement has been largely achieved as a result of international collaborative efforts through clinical trials [3] . In AML five-year survival rates reach up to 76% [4] .
Nonetheless, it seems that further intensification of treatment beyond the current standards is now maximized, and improvements in outcome have plateaued over the past decade [5] . Still, a substantial number of these patients will not be cured, and for those who survive long-term toxicities are of major importance [6] . Current efforts focus in particular clusters of patients with high-risk molecular or cytogenetic features, infants and relapsed or refractory leukemias [3] .
Molecular targeted agents have been developed in recent years in adult oncology, aiming at pathways that function predominantly in leukemic cells, ideally with absent or minimal function in healthy tissues. Such pathways may be initiated by cell surface receptors (CD33, CD22), specific intracellular kinases (FLT-3; BCR-ABL); proteins regulating cell death (BCL-2 family), and modulators of gene function [7] . However, in pediatric leukemia no other targeted agents have reached clinical practice besides tyrosine kinase inhibitors (TKI) in BCR-ABL rearranged ALL and CML.
The development of new agents in pediatrics virtually always lags behind that of the adults. Some reasons are: i) The success of frontline and even second line treatments results in a decreased number of children potentially able to participate in phase I-II trials; ii) The relatively small market of pediatric oncology does not provide the financial incentives for companies to actively pursue pediatric oncology drugs [8] ; iii)
Cancer biology in children is different from that of the adults in some diseases [9] ; iv)
Scarcity of preclinical pediatric models that allow to test broad-spectrum agents or In this manuscript we will review the progress made in the development of targeted agents in pediatric leukemia. Drugs selected for discussion have been chosen based on their pre-clinical data, mode of action, relevancy in pediatric leukemias and current degree of development (Figures 1 and 2 ). domains redirecting T-cell function [13] . Second and third generation CARs incorporate additional domains to supply co-stimulatory signals enhancing T-cell toxicity [13] .
CD19 CAR-T cells have yielded impressive results in adult chronic lymphocytic leukemia (CLL) with an overall response rate in the phase I trial approaching 60% in a heavily pretreated population [14] .
In children, two landmark early trials have shown exciting results in B-ALL creating major enthusiasm and social and media interest [15] . In pediatric trials, complete response (CR) rates ranged from 70 % to 90% [16, 17] and minimal residual disease (MRD) negativity rates of around 85% among those who achieved CR. In the Lee study, of those MRD negative patients, ten were able to proceed to hematopoietic stem cell transplantation (HSCT) and were still alive at last follow-up [17] . Interestingly, patients with central nervous system (CNS) disease cleared cerebrospinal fluid (CSF) blasts after treatment [16, 17] and no CNS relapses were observed [16] . Importantly, the feasibility rate of producing CD19 CAR-T cells was high (90%) [17] . The toxicity profile was mainly represented by the cytokine release syndrome (CRS) and hematological toxicities related to the lympho-depleting regimen.
A phase II trial of CD22 CAR-T cells is open for pediatric patients with relapsed/refractory CD22-expressing B cell malignancies (NCT02315612).
CD20 directed therapy
The surface antigen CD20 is present in 100% of children and adolescents with Burkitt lymphoma (BL) and 40% with B-ALL [18] . CD20 influences cell cycle progression and differentiation by modulating levels of proapotosis proteins and activation of surviving pathways [19] .
The most consolidated agent in this group is the chimeric mAb rituximab. Despite being widely used in adults and children, it still does not have a specific label for pediatric use. It has been used in combination with the hyper-CVAD regimen, as CD20 expression had been associated with higher relapse rates in adults with the novo B-cell ALL [20] . This combination significantly improved survival in adolescents and young adults with newly diagnosed CD20 B-ALL when compared with chemotherapy alone (3-year overall survival (OS) 75% Vs 47%) [19] . In pediatric high-risk B-mature acute leukemia and BL, addition of rituximab to conventional chemotherapy significantly improved their outcome: 1-year EFS was 94.2% Vs 81.5% for those not receiving rituximab [21] .
Ofatumumab targets a different epitope than rituximab. In adults with CD20 ALL, ofatumumab was added to the hyper-CVAD regimen. The 1-year PFS and OS were 91% [22] . Most common grade 3 toxic events were hepatic, thrombosis and neuropathy.
One trial is currently evaluating ofatumumab in newly diagnosed or first relapse B-cell ALL or lymphoblastic lymphoma (LL) children and adolescents with augmented BFM chemotherapy (NCT02419469).
CD19 directed therapy
CD19 is expressed ubiquitously on B cells from the pro/pre B-cell stage to mature Bcells and their malignant counterparts [23] . CD19 sustains the malignant B-cell phenotype via mechanisms of proliferation, cell survival and self-renewal [24] .
Blinatumomab is a bi-specific CD19-directed CD3 T-cell engager (BITE) facilitating the activation of endogenous T cells when bound to the CD19 expressing target cell regardless of the T cell receptor specificity or reliance on major histocompatibility complex (MHC) class I molecules on the surface of antigen presenting cells for activation [24] . This circumvents a known mechanism of resistance to T cell therapies through down-regulation of MHC class molecules. Blinatumomab was initially given as short IV infusions, but the absence of objective responses and the toxicity profile represented by CNS toxicities, CRS and infections, prompted its investigation as continuous infusion [24] . Initial phase II studies showing significant response rates in heavily pretreated patients led to considerable excitement and a conditional approval by the European Medicines Agency (EMA) in 2015 for adult relapsed ALL. A single arm phase II adult study in relapsed ALL demonstrated a CR rate of 33% (n=63) and CR with partial hematologic recovery (CRh) of 10% (n=18) after two cycles [25] . After a median follow up of 8.9 months, 37% of those eighty-one patients achieving CR/CRh were alive and in remission.
Blinatumomab in children has been investigated in thirty-nine patients with refractory or relapsed B-ALL as continuous IV infusion for 4 weeks up to 5 cycles [26] . During the first two cycles, twelve patients (31%) achieved CR, and of those five had complete MRD response. Six out of these twelve patients underwent bone marrow transplantation. Median relapse-free survival (RFS) for responding patients was 5.6
months. Most common severe adverse events (AEs) were anemia, pyrexia, increased ALT/AST and febrile neutropenia. Grade 3 CRS was reported in two patients (5%). In
Europe, a phase III trial (NCT02393859) will randomize high-risk relapsed B-cell ALL patients to receive blinatumomab or a conventional chemotherapy consolidation block before transplantation in a first step. In the adaptive phase of the study, patients will be randomized to receive blinatumomab or three consolidation chemotherapy blocks before transplant. In the US a phase III trial (NCT02101853) randomizes high and intermediate-risk relapsed B-cell ALL between blinatumomab and conventional chemotherapy following induction and low-risk patients between chemotherapy +/-blinatumumab following induction.
Coltuximab Ravtansine (SAR3419) is an anti-CD19 humanized mAB drug conjugate to DM4, a potent antimitotic agent. Coltuximab is active in pediatric models of B-ALL and infant mixed lineage leukemia (MLL) including chemo resistant Ph+ ALL [27] . In the phase I-II study of coltuximab single agent in relapsed B-ALL thirty-six adult patients were treated with manageable toxicities [28] . The recommended phase II dose (RP2D) was 70mg/m 2 given IV once weekly for 8 weeks.
Denintuzumab Mafodotin (SGN-CD19A) is a novel antibody-drug conjugate (ADC)
composed of a humanized anti-CD19 mAb conjugated to the microtubule-disrupting agent monomethyl auristatin F (MMAF), which binds to tubulin and induces G2/M arrest and apoptosis [29] . In the phase I study of denintuzumab single agent in relapsed B-ALL seventy-one adult patients participated [30] . Maximum tolerated dose (MTD) was 5mg/kg every 3 weeks and the MTD was not reached with the weekly dosing. The combined CR rate was 19% for the weekly dosing and 35% for the 3-weekly. AEs were similar with both schemas: gastrointestinal, ocular and hematological. The promising results in the Ph+ group have prompted an expansion cohort on the 3-weekly dosing.
CD 22 is expressed in more than 95% of B-cell ALL in children [31] . CD22 shifts from the cytoplasmic domain in developing B cells to the cell surface in later stages of B-Cell development.
Epratuzumab, a humanized anti-CD22 mAb, is internalized after binding to cell surface CD22 and modulates B-cell activation and signaling [32] . In the phase II COG study in ALL relapsed patients, epratuzumab was given once (B1) or twice weekly (B2) for a total of 4 or 8 doses during block 1 of re-induction [33] . CR rates after block 1 were similar for both cohorts and with the AALL01P2 study, a trial using the same chemotherapy (B1: 65%; B2: 66%; AALL01P2: 74%). Rates of MRD negativity were higher in this phase II study when compared with AALL01P2 (39% Vs 25%), results that should be interpreted with caution given the methodological difficulties of using historical controls. Early relapsed patients treated in cohort B2 had significant superior 2-year EFS when compared to AALL01P2 study (54.6% Vs. 25.7%,). IntReALL 2010
investigates the value of adding epratuzumab from induction to consolidation in a randomized fashion to two different regimens, the modified protocol ALL-REZ BFM 2002 and the UK ALL-R3 in standard risk relapsed ALL patients (NCT01802814).
Inotuzumab ozogamicin is a humanized mAb directed at CD22 that conjugates the moAb with calicheamicin, an antitumor antibiotic. A phase I-II study evaluated two different schedules in relapsed/refractory ALL including children [34] . The overall response rate was 58% and the CR rate was 19%. A total of 40% of patients could undergo transplantation afterwards. In adults with relapsed ALL, inotuzumab single agent was challenged against three standard relapse regimens. The CR rate was significantly higher with inotuzumab (80.7% Vs 29.4%) and more patients receiving inotuzumab had results below the MRD threshold (78.4% Vs 28.1%) [35] . Most frequent toxicity was veno-occlusive disease (VOD). An ITCC phase I-II study evaluating inotuzumab in children with refractory/relapsed ALL is launching this year in Europe (EudraCT 2016-000227-71).
Moxetumumab pasudotox is a recombinant immunoconjugate composed of an anti-CD22 immunoglobulin variable domain genetically fused to a truncated form of Pseudomonas exotoxin [36] . A phase I trial single agent in children and young adults with relapsed CD22+ hematological malignancies was associated with an acceptable toxicity profile (mainly hepatic). Objective responses were achieved in eleven patients (30%) including 9 (24%) CR [36] . A recent phase II study in pediatric relapsed ALL and LL has been early terminated because the required efficacy for the study continuation was not met (NCT02227108). Possible explanations for this limited activity are that higher doses are likely required to achieve maximal benefit and that drug exposure may be limited to rapid clearance [37] . To overcome these limitations, less immunogenic formulations that can be given at higher doses [38] and the combination with protein kinases enhancing its activity [39] are investigated.
CD33 directed therapy
The CD33 cell surface antigen is present in more than 80% of patients with AML [40] .
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody linked to the DNAbinding cytotoxin calicheamicin. Single agent activity was seen in a pediatric phase I study for relapsed AML with CR rates of 28% [41] . De novo AML children enrolled in the phase III COG trial AAML0531 were randomly assigned to receive or not GO during induction and consolidation [42] . Three-year EFS was significantly better in the GO group (53.1% Vs 46.9%) but there was not significant effect on OS (69.4% Vs 65.4%). FLT3/Internal Tandem Duplication (ITD)-positive de novo AML pediatric patients treated with GO and conventional chemotherapy and HSCT in first remission experienced less relapses in two consecutive COG trials [43] . GO may also have a role in the post-transplant setting as a consolidation regimen for those patients with AML, where its use has proved to be safe [44] and it is now investigated in a larger population (NCT02117297) where GO is given from day 60 to 180 post-transplant. In adults the addition of GO to daunorubicin and cytarabine resulted in a significantly higher fatal induction toxicity rate (mainly hemorrhages, VOD and other G4 non-hematological toxicities) [45] . This prompted its withdrawal from the US market in 2010 [46] .
Nonetheless, the interest for GO has been revived in AML after two large trials in newly diagnosed adult AML showed improvements in OS [47, 48] . An international phase III trial will randomize newly diagnosed AML pediatric patients to receive or not GO with conventional chemotherapy (NCT02724163). The key point is to find a balance between toxicity and efficacy. Low doses of 3mg/m 2 can have anti-leukemic effect and less undesirable side effects [49] .
In acute promyelocytic leukemia (APL) CD33 is expressed in virtually 100% of APL cells and GO has been better tolerated than conventional chemotherapy, particularly in older patients [50] . GO is currently under investigation in newly diagnosed APL in combination with ATRA and arsenic trioxide (NCT01409161).
SGN-CD33A is a novel ADC with a similar antileukemic activity to that of GO but without liver toxicity [51] . AMG 330 is a T-specific-cell-engaging antibody with dual specificity for CD3/CD33 that has shown promising activity in preclinical models and has now entered first in human clinical trials [52] .
The introduction of the TKI imatinib in front-line Ph+ ALL pediatric protocols radically changed the prognosis of these patients. Continuous use of imatinib along with conventional chemotherapy has improved the EFS of these patients from 29% to 81% [53] . In the COG-ALLL0031 study, the positive impact of continuous imatinib persisted regardless of the whether these patients were treated only with chemotherapy or received an allogeneic transplant [54] . A major drawback is the appearance of resistance, often through the development of point mutations in the ABL tyrosine kinase domain (ABL-TKD) [55] . Second generation TKI such as dasatinib and nilotinib are effective for M244V and H396P mutations [56] but not for T315I; dasatinib has been investigated in children with newly diagnosed Ph+ ALL (NCT00720109). Ponatinib is highly effective in T315I mutated Ph+ ALL [57] , although severe vascular side effects can occur [58] . Pediatric development for ponatinib has not started yet. A COG phase II study is now evaluating ruxolitinib in combination with chemotherapy in newly diagnosed high-risk Ph-like B-ALL patients (NCT02723994).
Ras/Raf/MEK/ERK
The mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival [67] and generates signal output through other effector pathways such as PI3K/AKT/mTOR and RalGEF/RAL [68] . Involved mechanisms in the activation of the Ras pathway include somatic mutations in upstream activators or regulatory proteins (NRAS, KRAS, BRAF, FLT3, PTPN11, CBL or NF1) and the incidence of these mutations in newly diagnosed ALL is up to 35% and 39% in relapsed patients [68] . In a series of 206 relapsed ALL patients, RAS mutant positive patients had a higher proportion of early relapses and shorter median time to relapse compared with wild type (WT) patients [69] . RAS mutations are an independent predictor for poor outcome in MLL rearranged infant ALL [70] Due to the difficulties in developing direct inhibitors of the RAS protein itself, efforts have focused on disrupting RAS post-translational processing. In this sense, tipifarnib, an orally bioavailable farnesyltransferase inhibitor, was tested in a phase I study including children with refractory leukemias [71] . The RP2D was established at 300mg/m and only one patient with JMML experienced stable disease (SD). Toxicities were mainly cutaneous and gastrointestinal.
MEK inhibition is an attractive approach in pediatric ALL, as it may be capable to inhibit the pathway regardless of the mechanism of upstream activation. The frequency of mutations in the RAS/RAF/MEK pathway is higher in prednisolone-resistant ALLchildren [72] . A complete sensitization to prednisolone after trametinib was observed in pediatric ALL cell lines, suggesting that MEK inhibition may modulate prednisolone resistance and improve clinical outcome of childhood B-ALL [72] . Selumetinib induced dramatic reduction in leukemia cells in mice with implanted RAS mutant ALL [69] .
Single agent activity was modest in untreated adult AML, but with favorable toxicity profile, suggesting its potential role in combination [73] .
FLT3 inhibitors
Activating mutations of the FLT3 gene have been described in pediatric ALL and AML, particularly in those with 11q23/MLL rearrangements [74] . Lestaurtinib, an FLT3
inhibitor, was found to be highly active in ALL cell lines with MLL gene rearrangements, high-hyperdiploidy and FLT3 mutations [75] . An ongoing phase III study for infants with newly diagnosed MLL rearranged ALL evaluates the addition of lestaurtinib in a randomized fashion to combination chemotherapy (NCT00557193).
Midostaurin single agent has been evaluated in a phase I/II trial in pediatric patients with relapsed/refractory leukemia [76] . The RP2D for combination studies is 30mg/m Sorafenib single agent and in combination has demonstrated to be active in pediatric AML mutant FLT3/ITD [77] . In the ongoing phase III COG AML trial (NCT01371981), high-risk FLT3/ITD+ patients receive sorafenib from induction.
Polo like kinases
Polo-Like Kinase 1 (PlK1) is a serine/threonine specific kinase implicated in several steps of cell mitosis [78] . Volasertib inhibits PlK1, resulting in cell cycle arrest and apoptosis [78] . Pre-clinical activity has been demonstrated in ALL, rhabdomyosarcoma (RMS), neuroblastoma and glioblastoma, both as single agent [78] and in RMS with chemotherapy [79] . A phase I dose escalation trial in refractory/relapsed pediatric tumors has been recently completed (NCT01971476). A phase I trial in children with AML after front line failure combines volasertib with chemotherapy (NCT02722135).
Proteasome inhibitors
Proteasome inhibitors have emerged as a one of the most promising therapeutics for hematological malignancies, particularly in adult multiple myeloma [80] . Pre-clinical studies indicate that malignant cells are more susceptible to their cytotoxic effects than normal cells. Several cellular processes contribute to their apoptotic effect: inhibition of NFκB activity, altered degradation of cell cycle related proteins, altered pro-apoptotic and anti-apoptotic protein balance, endoplasmic reticulum stress and inhibition of angiogenesis and DNA repair [80] .
Bortezomib, the first proteasome inhibitor authorized for multiple myeloma in adults, demonstrated activity in ALL cell lines and xenografts models [81] . The phase I trial of bortezomib with standard induction chemotherapy in children with relapsed ALL [82] defined the RP2D was 1.3mg/m CR. This schema was evaluated in a phase II study with 22 patients [83] and an 80% response rate in B-precursor patients. The COG evaluated the safety of bortezomib in combination with either idarubicine/cytarabine or cytarabine/etoposide in a cohort of forty-six patients with relapsed AML [84] . The CR rates were 29% and 43%
respectively. Toxicity is mainly hematological, infection and neuropathy. Toxicity on thrombopoiesis from bortezomib has been observed in adults with advance hematological malignancies and multiple myeloma [85] that may limit its development in certain hematological diseases, which does not seem to be such a frequent event in children [83] .
Bortezomib is under investigation in the phase III COG trial for newly diagnosed T-Cell ALL and lymphoma (NCT02112916) where patients are randomized to receive it or not during induction. In the European phase III BFM study in high-risk first relapsed ALL (EudraCT: 2012-000810-12), patients will be randomly assigned to receive or not bortezomib during induction. In AML, the phase III COG AML trial (NCT01371981) is currently randomizing newly diagnosed low and high-risk patients to receive or not bortezomib with combination chemotherapy.
Carfilzomib, a second-generation proteasome inhibitor, is under investigation in a pediatric phase I trial in relapsed ALL with conventional chemotherapy during induction (NCT02303821).
Epigenetic targeting
This section will cover drug candidates against epigenetic targets that have been described to play a role in pediatric leukemias.
DOT1L
Rearrangements in the MLL gene are present in up to 70% of patients with infant ALL [86] . The t(10;11)(p12;q23) and t(10;11)(p12;q14) translocations, which encode respectively the MLL-AF10 and CALM fusion proteins, are recurrent chromosomal rearrangements observed in acute leukemias [87, 88] . MLL-AF10 and CALM fusion proteins interact with histone H3 lysine 79(H3K79)-specific methyltransferase DOT1l.
Although DOT1L has not been found to be genetically altered in leukemia [89] , the interaction of these and others MLL-fusion proteins with DOT1L can lead to the mistargeting of DOT1L and subsequent methylation of H3K79, favoring leukemogenic transformation [90, 91] . EPZ5676 (pinometostat), a small molecule inhibitor of DOT1L H3K79 methyltransferase activity, has shown activity in cell lines bearing MLL-AF9, MLL-AF4, and MLL-ENL fusions [92] . A phase I trial investigating EPZ5676 single agent in pediatric patients with relapsed leukemia harboring rearrangements of the MLL gene has included eleven patients [93] , showing similar PK profiles between adults and children. No responses were observed.
Besides this, the BCL-2 anti-apoptotic proteins are utilized by the lymphoid malignancies to maintain viability under conditions of oncogenic stress [94] .
Chromatin-sequencing studies have shown that MLL/AF4 up-regulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3 [95] . The combination of ABT-199, a BCL-2 inhibitor, with DOT1L inhibitors (SGC0946 and EPZ5676) showed deep growth inhibition in t(4;11) cells ; a synergistic effect was also demonstrated when ABT-199 was combined with chemotherapy [95] . Targeting BCL-2 is an attractive approach for multiple hematological malignancies [96] and therefore ABT-199 is now being investigated in adult CLL, AML and other non-Hodgkin lymphomas.
Hypomethylating agents (DNMT)
DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues reduce methylation from promoter regulatory regions of tumor suppressor genes silenced by DNA methylation, which reactivates cell growth arrest and differentiation [97] .
Azacitidine (AzaC) and decitabine have been effectively used in the treatment of adult AML [98] .
In children, AzaC has been used in newly diagnosed and relapsed myelodisplastic syndrome (MDS) and JMML with promising and durable responses allowing patients entering HSCT in some cases [99, 100] . Two phase II clinical trials are evaluating AzaC in children with newly diagnosed and relapsed MDS and JMML (NCT02447666 and
EudraCT 2010-022235-10).
In pediatric AML, AzaC in combination with amsacrine and etoposide was active in refractory patients with AML, with a CR rate of 53% [101] . Decitabine has been evaluated as single agent as well as in combination with cytarabine but is not being taken forward into larger pediatric studies.
HDAC
Histone deacetylase (HDAC) inhibitors enhance histone acetylation leading to transcriptional repression and epigenetic silencing [102] . HDAC activity is increased in pediatric ALL and AML [103] . The use of HDAC inhibitors in MLL-rearranged ALL has been shown effective [104] . Vorinostat was evaluated in a phase I study in children with refractory tumors [105] . No responses were observed in the cohort of hematological malignancies. Vorinostat is currently under investigation in combination with chemotherapy and bortezomib for MLL-rearranged pediatric leukemias (NCT02419755). In ALL cell lines, vorinostat reprogramed the aberrant gene expression profile of relapsed blasts and the incorporation of decitabine led to reexpression of genes methylated and silenced at relapse [106] . These two drugs followed in combination with conventional chemotherapy have been applied in a pilot study including eight children [107] . Overall response rate was 46.2% and five patients could be transplanted. A TACL phase I trial of panobinostat single agent in pediatric patients with relapsed ALL and AML has been recently completed (NCT01321346).
Future directions
Over the last two years, major advances in the field of immunotherapy, mainly with the CAR-T cell therapy has demonstrated to be very effective in early studies in relapsed ALL, particularly in a fragile population where most patients had already undergone multiple treatment lines including allogeneic transplantation. After its approval for adults, blinatumomab has now entered phase III trials in first relapse pediatric high-risk B-ALL to test whether it may substitute conventional chemotherapy and serve as a less toxic bridge for transplantation. Inotuzumab single agent has been shown to be significantly more effective than other standard regimens for relapsed ALL in adults, and a pure pediatric trial is launching this year in Europe.
New BCR-ABL inhibitors are due to overcome the limitations on inherent or acquired resistance and toxicity when used in a prolonged fashion. Ponatinib is the first TKI demonstrating to be effective in T315I mutant Ph+ ALL, although its potential serious vascular associated events in children are a concern, lower doses may counteract for a better safety profile and bosutinib is expected to have a better safety profile.
FLT3 inhibition is a promising approach in MLL and FLT3-driven leukemias, a necessary driver of leukemogenesis particularly in infants. FLT3 inhibitors have a manageable toxicity profile and its capacity to be combined with already effective chemotherapeutics makes them very attractive. The addition of lestaurtinib to conventional chemotherapy in infants with ALL has already been investigated, and results still waited. Sorafenib is under investigation in newly diagnosed AML mutant
FLT3/ITD.
Proteasome inhibitors are also well advanced in their development. Bortezomib has reached phase III trials in newly diagnosed ALL. The addition of these agents to already intensive and toxic induction to remission regimens remains a concern and future strategies need to take into consideration this premise.
Conclusions
The impressive improvement in survival rates in pediatric leukemia, particularly ALL, between the early 60´s and 90´s is the most representative successful story in pediatric cancer. There has been no parallel before that or since then, notably because it has been achieved by using almost the same conventional chemotherapeutics that were available half a century ago. Our goal now is to continue improving these survival figures while minimizing the undesirable side effects of conventional treatment. New targeted therapies will truly contribute to this objective.
Integrating these novel agents into existing chemotherapy regimens and managing the additive side effects in an otherwise fragile population is complex. We have definitely entered into a new and fascinating era. Unveiling cancer genetics and discovering the mechanisms of escape of tumor cells opens the door to a more adapted therapy that will lead to improved outcomes for these patients.
Expert opinion
The development of new agents in pediatric leukemia and its incorporation into clinical practice remains challenging.
Key challenges and barriers are well known and, while not discussed in detail in this review, they are being addressed by academic researchers and collaborative studies. In summary, having identified the challenges and established the basis for more efficient preclinical and clinical drug development for pediatric leukemias, numerous agents are moving ahead in its development for pediatric leukemia and it is hoped that new drugs will reach clinical practice in coming years.
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